Skip to main content
Premium Trial:

Request an Annual Quote

FDA Accepts LabCorp's IDE Application for Atrial Fibrillation CDx

NEW YORK (GenomeWeb News) – Arca biopharma today said that Laboratory Corporation of America has told it that the US Food and Drug Administration has accepted LabCorp's investigational device exemption application for a companion diagnostic test for an atrial fibrillation drug under development.

The test is for use with Arca's Gencaro (bucindolol hydrochloride), a beta blocker and mild vasodilator, and the IDE allows the test to be used in a planned clinical trial for the drug.

Arca said that it identified common genetic variations that may predict individual patient response to Gencaro, and it and LabCorp developed the CDx test to identify patient genotypes based on the genetic variations of the beta-1 cardiac receptor. LabCorp is providing the patient genetic testing for Arca's clinical trial called Genetic-AF, which is anticipated to begin accepting patient enrollment in the current quarter. Medtronic is collaborating with Arca on the trial.

The FDA also has accepted Arca's investigational new drug application for Gencaro for treating atrial fibrillation, the Westminster, Colo.-based biopharmaceutical said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.